Download PDF
Thromb Haemost 1997; 77(02): 252-257
DOI: 10.1055/s-0038-1655948
Original Article
Schattauer GmbH Stuttgart

Molecular Characterization of a Type I Quantitative Factor V Deficiency in a Thrombosis Patient that Is “Pseudo Homozygous” for Activated Protein C Resistance

Joan F Guasch
The Haemostasis and Thrombosis Research Center, University Hospital Leiden, The Netherlands
,
Ruud P M Lensen
1   Department of Clinical Epidemiology, University Hospital Leiden, The Netherlands
,
Rogier M Bertina
The Haemostasis and Thrombosis Research Center, University Hospital Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 08 August 1996

Accepted after revision 28 October 1996

Publication Date:
10 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Resistance to activated protein C (APC), which is associated with the FV Leiden mutation in the large majority of the cases, is the most common genetic risk factor for thrombosis. Several laboratory tests have been developed to detect the APC-resistance phenotype. The result of the APC-resistance test (APC-sensitivity ratio, APC-SR) usually correlates well with the FV Leiden genotype, but recently some discrepancies have been reported. Some thrombosis patients that are heterozygous for FV Leiden show an APC-SR usually found only in homozygotes for the defect. Some of those patients proved to be compound heterozygotes for the FV Leiden mutation and for a type I quantitative factor V deficiency. We have investigated a thrombosis patient characterized by an APC-SR that would predict homozygosity for FV Leiden. DNA analysis showed that he was heterozygous for the mutation. Sequencing analysis of genomic DNA revealed that the patient also is heterozygous for a G5509→A substitution in exon 16 of the factor V gene. This mutation interferes with the correct splicing of intron 16 and leads to the presence of a null allele, which corresponds to the “non-FV Leiden” allele. The conjunction of these two defects in the patient apparently leads to the same phenotype as observed in homozygotes for the FV Leiden mutation.

 

  • References

  • 1 Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506
    CrossrefPubMedGoogle Scholar
  • 2 Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-1993
    PubMedGoogle Scholar
  • 3 Halbmayer WM, Haushofer A, Schon R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinol 1994; 5: 51-57
    CrossrefPubMedGoogle Scholar
  • 4 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522
    CrossrefPubMedGoogle Scholar
  • 5 Legnani C, Palareti G, Biagi R, Coccheri S. Activated protein C resistance in deep-vein thrombosis. Lancet 1994; 343: 541-542
    PubMedGoogle Scholar
  • 6 Cadroy Y, Sié P, Boneu B. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 1994; 83: 2008-2009
    PubMedGoogle Scholar
  • 7 Cushman M, Bhushan F, Bovill E, Tracy R. Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemost 1994; 72: 647-657
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923-927
    CrossrefPubMedGoogle Scholar
  • 9 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, deRonde H, van der VeldenPA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
    CrossrefPubMedGoogle Scholar
  • 10 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-1362
    PubMedGoogle Scholar
  • 11 Voorberg J, Roelse J, Koopman R, Büller H, Berends F, ten Cate JW, Mertens K, van MourikJA. Association of idiopathic venous thromboembolism with single point mutation at ARG506 of factor V. Lancet 1994; 343: 1535-1536
    CrossrefPubMedGoogle Scholar
  • 12 Zӧller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538
    CrossrefPubMedGoogle Scholar
  • 13 Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524
    CrossrefPubMedGoogle Scholar
  • 14 Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270: 4053-4057
    CrossrefPubMedGoogle Scholar
  • 15 Nicolaes GA, Tans G, Thomassen MC, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein. J Biol Chem 1995; 270: 21158-21166
    CrossrefPubMedGoogle Scholar
  • 16 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508
    PubMedGoogle Scholar
  • 17 Greengard JS, Eichinger S, Griffin JH, Bauer KA. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg→Gln mutation in the gene for factor V. N Engl J Med 1994; 331: 1559-1562
    CrossrefPubMedGoogle Scholar
  • 18 Hopmeier P, Krugluger W. Factory V Leiden and thrombophilia. N Engl J Med 1995; 332: 1381-1382
    CrossrefPubMedGoogle Scholar
  • 19 Simioni P, Scudeller A, Girolami A. Factor V Leiden and thrombophilia. N Engl J Med 1995; 332: 1382-1392
    PubMedGoogle Scholar
  • 20 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
    CrossrefPubMedGoogle Scholar
  • 21 deRonde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-886
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Vasse M, Leduc O, Borg JY, Chretien MH, Monconduit M. Resistance to activated protein C, evaluation of three functional assays. Thromb Res 1994; 76: 47-59
    CrossrefPubMedGoogle Scholar
  • 23 Sidelmann J, Gram J, Pedersen OD, Jespersen J. Influence of plasma platelets on activated protein C resistance assay. Thromb Haemost 1995; 74: 993-994
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Greengard JS, Alhenc-Gelas M, Gandrille S, Emmerich J, Aiach M, Griffin JH. Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V-R506Q and type I factor V deficiency associated with thrombosis. Thromb Haemost 1995; 73: 1361
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Simioni P, Scudeller A, Radossi P, Gavasso S, Girolami B, Tormene D, Girolami A. “Pseudo Homozygous” activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost 1996; 75: 422-426
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Zehnder JL, Jain M. Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency. Blood Coag Fibrinol 1996; 07: 361-362
    CrossrefPubMedGoogle Scholar
  • 27 Berg LP, Wieland K, Millar DS, Schlosser M, Wagner M, Kakkar VV, Reiss J, Cooper DN. Detection of a novel point mutation causing haemophilia A by PCR/direct sequencing of ectopically-transcribed factor VIII mRNA. Hum Genet 1990; 85: 655-658
    PubMedGoogle Scholar
  • 28 Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-453
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994; 83: 3120-3125
    PubMedGoogle Scholar
  • 30 Alhenc-Gelas M, Gandrille S, Aubry ML, Emmerich J, Flessinger JN, Aiach M. Unexplained thrombosis and factor V Leiden mutation. Lancet 1994; 344: 555-556
    PubMedGoogle Scholar
  • 31 Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR. High prevalence of a mutation in the factor V gene within the U.K population: relationship to activated protein C resistance and familial thrombosis. BrJ Haematol 1994; 88: 219-222
    CrossrefPubMedGoogle Scholar
  • 32 Murray JM, Rand MD, Egan JO, Murphy S, Kim HC, Mann KG. Factor V New Brunswick: Ala221-to-Val substitution results in reduced cofactor <activity. Blood 1995; 86: 1820-1827
    PubMedGoogle Scholar
  • 33 Kane WH, Ichinose A, Hagen FS, Davie EW. Cloning of cDNAs coding for the heavy chain region and connecting region of human factor V, a blood coagulation factor with four types of internal repeats. Biochemistry 1987; 26: 6508-6514
    CrossrefPubMedGoogle Scholar
  • 34 Cox MJ, Rees DC, Martinson JJ, Cleeg JB. Evidence for a single origin of factor V Leiden. Br J Haematol 1996; 92: 1022-1025
    CrossrefPubMedGoogle Scholar
  • 35 Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 1987; 84: 4846-4850
    CrossrefPubMedGoogle Scholar
  • 36 Kane WH, Davie EW. Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin. Proc Natl Acad Sci USA 1986; 83: 6800-6804
    CrossrefPubMedGoogle Scholar